DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q1 2022 vs. Q4 2021
How the institutions holding DBV Technologies S.A. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 41 | 31 | −10 |
| Shares | 21.3M | 20.4M | −951.5K (−4.5%) |
| Value | $34.7M | $32.9M | −$1.81M (−5.2%) |
New holders (3)
Institutions that held DBV Technologies S.A. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 22,116 | $35.0K | 0.00% |
| Geneos Wealth Management Inc. | 14,713 | $23.0K | 0.00% |
| UBS Group AG | 7,957 | $13.0K | 0.00% |
Sold out (13)
Institutions that held DBV Technologies S.A. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Credit Suisse AG | 77,067 | $123.0K |
| Virtu Financial LLC | 53,242 | $85.0K |
| Envestnet Asset Management Inc | 26,663 | $43.0K |
| Two Sigma Securities, LLC | 25,229 | $40.0K |
| Jane Street Group, LLC | 23,507 | $38.0K |
| FNY Investment Advisers, LLC | 20,000 | $32.0K |
| Signaturefd, LLC | 1,666 | $3.00K |
| US Bancorp | 1,446 | $2.00K |
| Lindbrook Capital, LLC | 1,470 | $2.00K |
| Tower Research Capital LLC (TRC) | 355 | $1.00K |
| Parallel Advisors, LLC | 428 | $1.00K |
| Barclays PLC | 74 | $0 |
| Quadrant Capital Group LLC | 196 | $0 |